Target-attainment rates of low-density lipoprotein cholesterol using lipid-lowering drugs one year after acute myocardial infarction in Sweden

American Journal of Cardiology

Volumn 113, Issue 1, 2014, Pages 17-22

  Hambraeus, Kristina ^a,b   Lindhagen, Lars ^c   Tydén, Patrik ^d   Lindahl, Bertil ^b   Lagerqvist, Bo ^b  

^a FALUN HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c UPPSALA CLINICAL RESEARCH CENTER   (Sweden)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; EZETIMIBE; FLUINDOSTATIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ACUTE HEART INFARCTION; ADULT; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CORRELATIONAL STUDY; DRUG USE; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; INTENSIVE CARE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MOLECULARLY TARGETED THERAPY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN TARGETING; SWEDEN; TREATMENT DURATION;

AGED; CHOLESTEROL, LDL; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOLIPIDEMIC AGENTS; MALE; MIDDLE AGED; MORBIDITY; MYOCARDIAL INFARCTION; PROSPECTIVE STUDIES; SURVIVAL RATE; SWEDEN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84890431615     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2013.09.007     Document Type: Article

References (20)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 344 1994 1383 1389
2. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo controlled trial Lancet 360 2002 7 22
3. Cholesterol Treatment Trialists C, C. Baigent, L. Blackwell, J. Emberson, L.E. Holland, C. Reith, N. Bhala, R. Peto, E.H. Barnes, A. Keech, J. Simes, and R. Collins Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 2010 1670 1681
4. G. De Backer, E. Ambrosioni, K. Borch-Johnsen, C. Brotons, R. Cifkova, J. Dallongeville, S. Ebrahim, O. Faergeman, I. Graham, G. Mancia, V.M. Cats, K. Orth-Gomer, J. Perk, K. Pyorala, J.L. Rodicio, S. Sans, V. Sansoy, U. Sechtem, S. Silber, T. Thomsen, D. Wood European Society of Cardiology Committee for Practice G European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts) Eur J Cardiovasc Prev Rehabil 10 2003 S1 S10
5. I. Graham, D. Atar, K. Borch-Johnsen, G. Boysen, G. Burell, R. Cifkova, J. Dallongeville, G. De Backer, S. Ebrahim, B. Gjelsvik, C. Herrmann-Lingen, A. Hoes, S. Humphries, M. Knapton, J. Perk, S.G. Priori, K. Pyorala, Z. Reiner, L. Ruilope, S. Sans-Menendez, W.S. Op Reimer, P. Weissberg, D. Wood, J. Yarnell, J.L. Zamorano, E. Walma, T. Fitzgerald, M.T. Cooney, A. Dudina, A. Vahanian, J. Camm, R. De Caterina, V. Dean, K. Dickstein, C. Funck-Brentano, G. Filippatos, I. Hellemans, S.D. Kristensen, K. McGregor, U. Sechtem, S. Silber, M. Tendera, P. Widimsky, A. Altiner, E. Bonora, P.N. Durrington, R. Fagard, S. Giampaoli, H. Hemingway, J. Hakansson, S.E. Kjeldsen, L. Larsen, G. Mancia, A.J. Manolis, K. Orth-Gomer, T. Pedersen, M. Rayner, L. Ryden, M. Sammut, N. Schneiderman, A.F. Stalenhoef, L. Tokgozoglu, O. Wiklund, A. Zampelas, European Society of Cardiology (ESC), European Association for Cardiovascular Prevention, Rehabilitation (EACPR); Council on Cardiovascular Nursing, European Association for Study of Diabetes (EASD), International Diabetes Federation Europe (IDF-E), European Stroke Initiative (EUSI); Society of Behavioural Medicine (ISBM), European Society of Hypertension (ESH), WONCA Europe (European Society of General Practice/Family Medicine), European Heart N, and European Atherosclerosis Society (EAS) European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts) Eur J Cardiovasc Prev Rehabil 14 2007 S1 113
6. Swedish National Board of Health and Welfare. National Guidelines for Coronary Artery Disease. 2008:160.
7. European Association for Cardiovascular Prevention & Rehabilitation, Z. Reiner, A.L. Catapano, G. De Backer, I. Graham, M.R. Taskinen, O. Wiklund, S. Agewall, E. Alegria, M.J. Chapman, P. Durrington, S. Erdine, J. Halcox, R. Hobbs, J. Kjekshus, P.P. Filardi, G. Riccardi, R.F. Storey, D. Wood, ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees, J. Bax, A. Vahanian, A. Auricchio, H. Baumgartner, C. Ceconi, V. Dean, C. Deaton, R. Fagard, G. Filippatos, C. Funck-Brentano, D. Hasdai, A. Hoes, P. Kearney, J. Knuuti, P. Kolh, T. McDonagh, C. Moulin, D. Poldermans, B.A. Popescu, U. Sechtem, P.A. Sirnes, M. Tendera, A. Torbicki, P. Vardas, P. Widimsky, S. Windecker, G. Berkenboom, J. De Graaf, O. Descamps, N. Gotcheva, K. Griffith, G.F. Guida, S. Gulec, Y. Henkin, K. Huber, Y.A. Kesaniemi, J. Lekakis, A.J. Manolis, P. Marques-Vidal, L. Masana, J. McMurray, M. Mendes, Z. Pagava, T. Pedersen, E. Prescott, Q. Rato, G. Rosano, S. Sans, A. Stalenhoef, L. Tokgozoglu, M. Viigimaa, M.E. Wittekoek, J.L. Zamorano, Z. Reiner, A.L. Catapano, G. De Backer, I. Graham, M.-R. Taskinen, O. Wiklund, S. Agewall, E. Alegria, M.J. Chapman, P. Durrington, S. Erdine, J. Halcox, R. Hobbs, J. Kjekshus, P.P. Filardi, G. Riccardi, R.F. Storey, D. Wood, J. Bax, A. Vahanian, A. Auricchio, H. Baumgartner, C. Ceconi, V. Dean, C. Deaton, R. Fagard, G. Filippatos, C. Funck-Brentano, D. Hasdai, A. Hoes, P. Kearney, J. Knuuti, P. Kolh, T. McDonagh, C. Moulin, D. Poldermans, B.A. Popescu, U. Sechtem, P.A. Sirnes, M. Tendera, A. Torbicki, P. Vardas, P. Widimsky, S. Windecker, G. Berkenboom, J. De Graaf, O. Descamps, N. Gotcheva, K. Griffith, G.F. Guida, S. Gulec, Y. Henkin, K. Huber, Y.A. Kesaniemi, J. Lekakis, A.J. Manolis, P. Marques-Vidal, L. Masana, J. McMurray, M. Mendes, Z. Pagava, T. Pedersen, E. Prescott, Q. Rato, G. Rosano, S. Sans, A. Stalenhoef, L. Tokgozoglu, M. Viigimaa, and J.L. Zamorano ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) Eur Heart J 32 2011 1769 1818
8. K. Kotseva, D. Wood, G. De Backer, D. De Bacquer, K. Pyorala, U. Keil, E.S. Group, K. Kotseva, D. Wood, G. De Backer, D. De Bacquer, K. Pyorala, and U. Keil Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries Lancet 373 2009 929 940
9. T. Jernberg, M.F. Attebring, K. Hambraeus, T. Ivert, S. James, A. Jeppsson, B. Lagerqvist, B. Lindahl, U. Stenestrand, L. Wallentin, T. Jernberg, M.F. Attebring, K. Hambraeus, T. Ivert, S. James, A. Jeppsson, B. Lagerqvist, B. Lindahl, U. Stenestrand, and L. Wallentin The Swedish Web-system for enhancement and development of evidence-based care in heart disease evaluated according to recommended therapies (SWEDEHEART) Heart 96 2010 1617 1621
10. B. Wettermark, N. Hammar, C.M. Fored, A. Leimanis, P. Otterblad Olausson, U. Bergman, I. Persson, A. Sundstrom, B. Westerholm, M. Rosen, B. Wettermark, N. Hammar, C.M. Fored, A. Leimanis, P. Otterblad Olausson, U. Bergman, I. Persson, A. Sundstrom, B. Westerholm, and M. Rosen The new Swedish Prescribed Drug Register - opportunities for pharmacoepidemiological research and experience from the first six months Pharmacoepidemiol Drug Saf 16 2007 726 735
11. M.R. Law, N.J. Wald, and A.R. Rudnicka Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis BMJ 326 2003 1423
12. J. Hallas, D. Gaist, and L. Bjerrum The waiting time distribution as a graphical approach to epidemiologic measures of drug utilization Epidemiology 8 1997 666 670
13. C.P. Cannon, E. Braunwald, C.H. McCabe, D.J. Rader, J.L. Rouleau, R. Belder, S.V. Joyal, K.A. Hill, M.A. Pfeffer, A.M. Skene, and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 2004 1495 1504
14. U. Javed, P.C. Deedwania, D.L. Bhatt, C.P. Cannon, D. Dai, A.F. Hernandez, E.D. Peterson, G.C. Fonarow, U. Javed, P.C. Deedwania, D.L. Bhatt, C.P. Cannon, D. Dai, A.F. Hernandez, E.D. Peterson, and G.C. Fonarow Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: an analysis of 65,396 hospitalizations from 344 hospita participating in Get With The Guidelines (GWTG) Am Heart J 161 2011 418 424 e411-413
15. K. Kotseva, D. Wood, G. De Backer, D. De Bacquer, K. Pyorala, U. Keil, E.S. Group, K. Kotseva, D. Wood, G. De Backer, D. De Bacquer, K. Pyorala, and U. Keil EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries Eur J Cardiovasc Prev Rehabil 16 2009 121 137
16. M.J. Koren, D.B. Hunninghake, A. Investigators, M.J. Koren, and D.B. Hunninghake Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study J Am Coll Cardiol 44 2004 1772 1779
17. L. Wei, T.M. MacDonald, A.D. Watson, and M.J. Murphy Effectiveness of two statin prescribing strategies with respect to adherence and cardiovascular outcomes: observational study Pharmacoepidemiol Drug Saf 16 2007 385 392
18. J. Perk, G. De Backer, H. Gohlke, I. Graham, Åe Reiner, M. Verschuren, C. Albus, P. Benlian, G. Boysen, R. Cifkova, C. Deaton, S. Ebrahim, M. Fisher, G. Germano, R. Hobbs, A. Hoes, S. Karadeniz, A. Mezzani, E. Prescott, L. Ryden, M. Scherer, M. Syvänne, W.J.M. Scholte Op Reimer, C. Vrints, D. Wood, J.L. Zamorano, F. Zannad, guidelines: Oewctpot, M.T. Cooney ESC Committee for Practice Guidelines J. Bax, H. Baumgartner, C. Ceconi, V. Dean, R. Fagard, C. Funck-Brentano, D. Hasdai, P. Kirchhof, J. Knuuti, P. Kolh, T. McDonagh, C. Moulin, B.A. Popescu, U. Sechtem, P.A. Sirnes, M. Tendera, A. Torbicki, A. Vahanian, S. Windecker, Reviewers: D, V. Aboyans, E.A. Ezquerra, C. Baigent, C. Brotons, G. Burell, A. Ceriello, J. De Sutter, J. Deckers, S. Del Prato, H.-C. Diener, D. Fitzsimons, Z. Fras, R. Hambrecht, P. Jankowski, U. Keil, M. Kirby, M.L. Larsen, G. Mancia, A.J. Manolis, J. McMurray, A. Paja̧k, A. Parkhomenko, L. Rallidis, F. Rigo, E. Rocha, L.M. Ruilope, E. van der Velde, D. Vanuzzo, M. Viigimaa, M. Volpe, O. Wiklund, and C. Wolpert European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) Eur Heart J 33 2012 1635 1701
19. R. Ara, A. Pandor, J. Stevens, A. Rees, and R. Rafia Early high-dose lipid-lowering therapy to avoid cardiac events: a systematic review and economic evaluation Health Technol Assess 13 2009 1 74
20. Harnek J, Nilsson J, Friberg O, James S, Lagerqvist B, Hambraeus K, Cider A, Svennberg L, Attebring MF, Held C, Johansson P, Jernberg T. The 2011 outcome from the Swedish Health care registry on heart disease (SWEDEHEART). Scand Cardiovasc J 2013;47(suppl)62:1-10.